1. Home
  2. TSE vs VTYX Comparison

TSE vs VTYX Comparison

Compare TSE & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trinseo PLC

TSE

Trinseo PLC

HOLD

Current Price

$0.62

Market Cap

68.0M

Sector

Industrials

ML Signal

HOLD

Logo Ventyx Biosciences Inc.

VTYX

Ventyx Biosciences Inc.

HOLD

Current Price

$8.17

Market Cap

713.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSE
VTYX
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.0M
713.6M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
TSE
VTYX
Price
$0.62
$8.17
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$1.00
$14.60
AVG Volume (30 Days)
671.3K
1.7M
Earning Date
11-06-2025
11-06-2025
Dividend Yield
4.80%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,133,800,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.47
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.60
$0.78
52 Week High
$6.85
$10.55

Technical Indicators

Market Signals
Indicator
TSE
VTYX
Relative Strength Index (RSI) 28.67 47.12
Support Level $0.60 $8.39
Resistance Level $0.76 $9.13
Average True Range (ATR) 0.08 0.63
MACD 0.01 -0.25
Stochastic Oscillator 8.44 20.35

Price Performance

Historical Comparison
TSE
VTYX

About TSE Trinseo PLC

Trinseo PLC is a materials company and manufacturer of latex and plastics products. The company's operating segments include Latex Binders, Americas Styrenics, Engineered Materials, and Polymer Solutions. Maximum revenue is generated from its Polymer Solutions segment, which consists of various polymers, the majority of which are for automotive, building, and construction applications. The product offerings of this segment include ABS, styrene-acrylonitrile, polystyrene, and polycarbonate products, which are marketed through brands like Magnum and Styron. Geographically, the company generates maximum revenue from Europe, followed by the United States, Asia-Pacific, and the Rest of the world.

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Share on Social Networks: